DVAX
$3.15
Dynavax Technologies
$.14
4.65%
DVAX
Earnings Whisper ®
N/A
1st Quarter March 2020
Consensus:  ($0.31)
Revenue:  $11.76 Mil
Wednesday
Jun 10
4:10 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when DVAX reports earnings?
Beat
Meet
Miss

Where is DVAX's stock price going from here?
Up
Flat
Down
Stock chart of DVAX
Analysts
Summary of analysts' recommendations for DVAX
Score
Grade
Pivots
Resistance
$3.48
$3.32
$3.23

$3.07

Support
$2.98
$2.82
$2.73
Tweet
Growth
Description
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Peers
Regeneron PharmaceuticalsBioMarin PharmaceuticalVertex PharmaceuticalsJohnson & JohnsonInterCeptZoetisBristol-Myers SquibbMylanUltragenyx PharmaceuticalAlkermes